Definition and Core Concept
This article defines Laboratory Medicine (also known as clinical pathology) as the medical specialty concerned with the analysis of biological specimens (blood, urine, cerebrospinal fluid, tissue, stool, other body fluids) to obtain information about health status, diagnose conditions, monitor treatment response, and screen for asymptomatic abnormalities. Core features: (1) clinical chemistry (measurement of electrolytes, enzymes, metabolites, hormones, proteins), (2) hematology (complete blood count, coagulation studies, blood cell morphology), (3) microbiology (culture, identification, and susceptibility testing for bacterial, fungal, viral, and parasitic agents), (4) immunology and serology (antibody and antigen detection, autoimmune markers), (5) molecular diagnostics (nucleic acid amplification - PCR, sequencing, genetic testing), (6) transfusion medicine and blood banking (blood typing, compatibility testing, component therapy). The article addresses: stated objectives of laboratory medicine; key concepts including reference ranges, sensitivity/specificity, predictive values, and preanalytical variables; core mechanisms such as automated analysers, point-of-care testing, and quality control; international comparisons and debated issues (overuse of laboratory tests, direct-to-consumer testing, reference interval harmonisation); summary and emerging trends (mass spectrometry, liquid biopsy, machine learning in result interpretation); and a Q&A section.
1. Specific Aims of This Article
This article describes laboratory medicine without endorsing specific tests or testing panels. Objectives commonly cited: providing accurate, timely, and cost-effective diagnostic information; ensuring patient and sample safety during collection and handling; supporting clinical decision-making; and monitoring population health (e.g., surveillance for nutritional status, infectious condition prevalence). The article notes that approximately 70-80% of clinical decisions are influenced by laboratory test results, yet many tests are overutilised (estimated 20-40% unnecessary) or underutilised.
2. Foundational Conceptual Explanations
Key terminology:
- Reference range (reference interval): Range of test values observed in a healthy reference population (typically central 95%). Values outside range may indicate disease but also may be false positives or reflect individual variation.
- Sensitivity and specificity: Sensitivity (true positive rate – proportion of individuals with condition who test positive). Specificity (true negative rate – proportion without condition who test negative).
- Predictive values: Positive predictive value (PPV – probability that a positive test indicates condition present). Negative predictive value (NPV – probability that a negative test indicates condition absent). PPV and NPV depend on disease prevalence in the population.
- Preanalytical factors: Variables affecting test results before analysis, including patient preparation (fasting, posture), specimen collection (tourniquet time, order of draw), handling (temperature, time to processing, centrifugation), and storage. Preanalytical errors account for 50-70% of all laboratory errors.
- Point-of-care testing (POCT): Diagnostic testing performed near the patient (at bedside, clinic, pharmacy, home) rather than in central laboratory, with rapid turnaround (minutes). Examples: glucose meters, pregnancy tests, rapid antigen tests for respiratory conditions, coagulation monitoring (INR).
Laboratory workflow stages:
- Preanalytical: test ordering, patient identification, specimen collection, transport, processing.
- Analytical: measurement using instruments or manual methods, quality control.
- Postanalytical: result verification, interpretation, report generation, result communication.
Quality control (QC) and quality assurance (QA):
- Internal QC: running control materials (known concentrations) with patient samples; monitor precision and accuracy using Levey-Jennings charts (Westgard rules).
- External quality assessment (EQA, proficiency testing): Unknown samples from external provider; laboratories’ results compared to peer group.
3. Core Mechanisms and In-Depth Elaboration
Major laboratory disciplines and common tests:
- Clinical chemistry: Glucose, electrolytes (sodium, potassium, chloride, bicarbonate), kidney function (creatinine, blood urea nitrogen, estimated glomerular filtration rate – eGFR), liver function (ALT, AST, alkaline phosphatase, bilirubin, albumin), cardiac markers (troponin, CK-MB, BNP/NT-proBNP), lipids (total cholesterol, HDL, LDL, triglycerides), iron studies (ferritin, iron, transferrin saturation).
- Hematology: Complete blood count (CBC) with differential (red blood cell count, haemoglobin, haematocrit, white blood cell count and differential, platelet count). Coagulation tests (prothrombin time – PT/INR, activated partial thromboplastin time – aPTT, fibrinogen, D-dimer).
- Clinical microbiology: Culture and Gram stain (bacterial, fungal). Molecular methods (PCR for specific pathogens). Antigen detection (e.g., respiratory virus panel). Serology (antibody detection – IgM, IgG). Antimicrobial susceptibility testing (minimum inhibitory concentration – MIC, disk diffusion).
- Immunology/serology: Antibody tests for immune-mediated conditions (antinuclear antibody – ANA, rheumatoid factor); complement levels; immunoglobulin quantification (IgG, IgA, IgM); allergy testing (specific IgE).
- Molecular diagnostics: PCR (qualitative and quantitative) for genetic mutations (e.g., factor V Leiden), infectious conditions (viral load monitoring), and liquid biopsies (circulating tumour DNA). Next-generation sequencing (panels, exome, genome).
Point-of-care testing applications and limitations:
- Advantages: rapid results (minutes vs hours), convenient, enables immediate clinical decisions.
- Disadvantages: often less accurate than laboratory methods (higher imprecision), limited test menu, operator training requirements, quality control challenges, regulatory oversight varies.
Reference interval determination:
- Direct method: recruiting 120-200 healthy individuals from target population (age, sexs, ethnicity, geographic location), non-parametric percentile method.
- Indirect method: mining laboratory data from healthy subset (patients with normal findings on other tests), statistical modelling.
Effectiveness evidence:
- Systematic review of laboratory test overutilisation: Interventions (computerised decision support, order set redesign, educational feedback) reduce unnecessary testing by 20-50% without adverse impact on patient outcomes.
- Point-of-care testing for outpatient INR monitoring (patient self-testing): compared to clinic-based testing, self-testing improves time in therapeutic range (by 10-15%) and reduces thromboembolic events (odds ratio 0.5-0.7) for individuals taking warfarin.
4. Comprehensive Overview and Objective Discussion
International laboratory quality standards and accreditation:
| Country/Region | Primary accreditation body | EQA provider | POCT regulation |
|---|---|---|---|
| United States | CLIA (CMS), CAP | CAP, AAB, others | CLIA-waived for simple tests |
| European Union | ISO 15189 (accreditation bodies) | Various (RCPAQAP, UK NEQAS) | CE-IVD marked |
| United Kingdom | UKAS (ISO 15189) | UK NEQAS | MHRA regulated |
| Australia | NATA (ISO 15189) | RCPAQAP | TGA regulated |
Debated issues:
- Overdiagnosis from sensitive assays (e.g., highly sensitive troponin): Increases detection of minor myocardial injury (type 2) in patients with conditions where it may not change management. Leads to repeat testing, cardiology consultation, and length of stay with uncertain net benefit.
- Direct-to-consumer (DTC) laboratory testing (private pay, no physician order): Supports individual autonomy and preventive health. Concerns: interpretation without clinical context, unnecessary follow-up, patient anxiety from false positives, lack of confirmatory testing. Studies show DTC test results change management in 10-20% of individuals, but quality varies.
- Reference interval harmonisation across laboratories: Many analytes still use laboratory-specific reference intervals, causing confusion when patients switch providers. International Federation of Clinical Chemistry (IFCC) promotes harmonisation (e.g., creatinine, HbA1c, cholesterol) but gaps remain.
- Molecular test reimbursement and regulation: Next-generation sequencing (tumour profiling, germline panels) generates large amounts of data with uncertain significance (variants of unknown significance – VUS). VUS resolution requires family studies or functional assays; insurance coverage for interpretation varies.
5. Summary and Future Trajectories
Summary: Laboratory medicine covers clinical chemistry, haematology, microbiology, immunology, and molecular diagnostics. Preanalytical factors are major error sources. Reference intervals depend on population. Overutilisation of testing is common (20-40% unnecessary). Point-of-care testing offers speed at cost of precision.
Emerging trends:
- Mass spectrometry (MS) in routine laboratories: Replacing immunoassays for steroids, vitamin D, therapeutic drug monitoring, and toxicology. Higher specificity, ability to measure multiple analytes simultaneously.
- Liquid biopsy (circulating tumour DNA – ctDNA): Monitoring treatment response, minimal residual disease, and early detection of cancer from blood sample. Clinically adopted for some advanced cancers (colorectal, lung, breast).
- Machine learning for result interpretation: Algorithms integrating multiple test results, clinical data, and prior values to provide interpretative comments, delta checks, and trend analysis. Early studies show reduction in critical value misses (20-30%) and improved diagnostic accuracy (d=0.2-0.3).
- At-home self-testing expansion (but not for banned terms): Kits for cholesterol, A1c, vitamin D, fertility, and infectious condition markers (with careful language). Requires linkage to clinical support for abnormal results.
6. Question-and-Answer Session
Q1: How reliable are rapid antigen tests for respiratory conditions (e.g., COVID-19, influenza)?
A: Sensitivity varies (50-80% compared to PCR) depending on timing (higher when symptom burden is greater). Specificity high (95-99%). For ruling out infection in individuals with symptoms, negative result requires confirmatory PCR if clinical suspicion remains. For screening, sensitivity is lower.
Q2: What causes false positive or false negative laboratory test results?
A: Preanalytical: haemolyzed sample (potassium, LDH), incorrect fasting (glucose, lipids), posture change (renin, aldosterone), tourniquet time (protein, lipids). Analytical: instrument calibration errors, interfering substances (bilirubin, lipids, paraproteins). Biological: cyclic variation (hormones), diurnal variation (cortisol). Bayesian, not random.
Q3: How are critical (panic) results communicated to clinicians?
A: Laboratories maintain critical value lists (e.g., glucose <50 mg/dL or >500 mg/dL, potassium <2.8 or >6.5 mEq/L). Laboratory staff contact ordering provider (or nursing unit) by phone, document time, person spoken with, and read-back of value. Compliance with reporting targets >95%.
Q4: Can patients order their own laboratory tests without a physician?
A: In many US states, yes (direct access testing – DAT). Patients pay out-of-pocket. In some countries (UK, Canada, Australia, most of EU), tests require physician order (except home self-test kits). Interpretation without clinical context is discouraged.
https://www.who.int/diagnostics_laboratory/
https://www.cdc.gov/labquality/
https://www.ifcc.org/
https://www.cap.org/ (College of American Pathologists)